Trust Company of Vermont’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $68.5K | Sell |
389
-660
| -63% | -$108K | ﹤0.01% | 515 |
|
|
2025
Q3 | $147K | Hold |
1,049
| – | – | 0.01% | 390 |
|
|
2025
Q2 | $132K | Hold |
1,049
| – | – | 0.01% | 392 |
|
|
2025
Q1 | $144K | Hold |
1,049
| – | – | 0.01% | 369 |
|
|
2024
Q4 | $160K | Sell |
1,049
-20
| -2% | -$3.37K | 0.01% | 368 |
|
|
2024
Q3 | $207K | Hold |
1,069
| – | – | 0.01% | 326 |
|
|
2024
Q2 | $248K | Sell |
1,069
-1,116
| -51% | -$243K | 0.01% | 294 |
|
|
2024
Q1 | $471K | Sell |
2,185
-9
| -0.4% | -$2.11K | 0.03% | 235 |
|
|
2023
Q4 | $568K | Sell |
2,194
-74
| -3% | -$18.2K | 0.04% | 198 |
|
|
2023
Q3 | $583K | Buy |
2,268
+12
| +0.5% | +$3.21K | 0.04% | 205 |
|
|
2023
Q2 | $643K | Sell |
2,256
-2
| -0.1% | -$595 | 0.04% | 205 |
|
|
2023
Q1 | $628K | Buy |
2,258
+37
| +2% | +$10.2K | 0.04% | 205 |
|
|
2022
Q4 | $615K | Buy |
2,221
+16
| +0.7% | +$4.52K | 0.05% | 208 |
|
|
2022
Q3 | $589K | Sell |
2,205
-1
| -0% | -$212 | 0.05% | 205 |
|
|
2022
Q2 | $450K | Sell |
2,206
-11
| -0.5% | -$2.25K | 0.03% | 222 |
|
|
2022
Q1 | $467K | Sell |
2,217
-14
| -0.6% | -$3.04K | 0.03% | 228 |
|
|
2021
Q4 | $535K | Sell |
2,231
-121
| -5% | -$31.1K | 0.03% | 219 |
|
|
2021
Q3 | $665K | Sell |
2,352
-89
| -4% | -$29.2K | 0.05% | 197 |
|
|
2021
Q2 | $845K | Buy |
2,441
+762
| +45% | +$231K | 0.06% | 176 |
|
|
2021
Q1 | $470K | Sell |
1,679
-73
| -4% | -$19.7K | 0.04% | 221 |
|
|
2020
Q4 | $429K | Sell |
1,752
-770
| -31% | -$199K | 0.03% | 219 |
|
|
2020
Q3 | $716K | Buy |
2,522
+31
| +1% | +$8.65K | 0.07% | 171 |
|
|
2020
Q2 | $666K | Sell |
2,491
-250
| -9% | -$75.1K | 0.07% | 175 |
|
|
2020
Q1 | $867K | Buy |
2,741
+72
| +3% | +$21.9K | 0.08% | 162 |
|
|
2019
Q4 | $792K | Buy |
2,669
+37
| +1% | +$10.3K | 0.06% | 189 |
|
|
2019
Q3 | $613K | Sell |
2,632
-167
| -6% | -$38.9K | 0.05% | 208 |
|
|
2019
Q2 | $654K | Sell |
2,799
-215
| -7% | -$49.6K | 0.05% | 200 |
|
|
2019
Q1 | $712K | Buy |
3,014
+4
| +0.1% | +$1.26K | 0.06% | 194 |
|
|
2018
Q4 | $906K | Sell |
3,010
-32
| -1% | -$10.2K | 0.09% | 169 |
|
|
2018
Q3 | $1.07M | Sell |
3,042
-135
| -4% | -$46.5K | 0.09% | 167 |
|
|
2018
Q2 | $922K | Buy |
3,177
+45
| +1% | +$12.7K | 0.08% | 174 |
|
|
2018
Q1 | $857K | Sell |
3,132
-74
| -2% | -$23K | 0.08% | 173 |
|
|
2017
Q4 | $1.02M | Buy |
3,206
+25
| +0.8% | +$8.02K | 0.09% | 171 |
|
|
2017
Q3 | $996K | Buy |
3,181
+75
| +2% | +$22.2K | 0.1% | 167 |
|
|
2017
Q2 | $843K | Buy |
3,106
+694
| +29% | +$184K | 0.09% | 172 |
|
|
2017
Q1 | $660K | Buy |
2,412
+7
| +0.3% | +$1.98K | 0.07% | 190 |
|
|
2016
Q4 | $682K | Buy |
2,405
+362
| +18% | +$107K | 0.08% | 181 |
|
|
2016
Q3 | $640K | Buy |
2,043
+540
| +36% | +$160K | 0.08% | 171 |
|
|
2016
Q2 | $364K | Buy |
1,503
+304
| +25% | +$80.1K | 0.05% | 203 |
|
|
2016
Q1 | $312K | Buy |
1,199
+14
| +1% | +$3.7K | 0.04% | 208 |
|
|
2015
Q4 | $363K | Buy |
1,185
+278
| +31% | +$79.9K | 0.05% | 202 |
|
|
2015
Q3 | $264K | Buy |
907
+125
| +16% | +$41.3K | 0.04% | 215 |
|
|
2015
Q2 | $316K | Buy |
782
+157
| +25% | +$63K | 0.05% | 204 |
|
|
2015
Q1 | $264K | Buy |
625
+100
| +19% | +$39.4K | 0.04% | 214 |
|
|
2014
Q4 | $178K | Hold |
525
| – | – | 0.03% | 242 |
|
|
2014
Q3 | $174K | Buy |
525
+16
| +3% | +$5.28K | 0.03% | 239 |
|
|
2014
Q2 | $161K | Hold |
509
| – | – | 0.02% | 239 |
|
|
2014
Q1 | $156K | Hold |
509
| – | – | 0.03% | 244 |
|
|
2013
Q4 | $142K | Buy |
509
+345
| +210% | +$89.2K | 0.02% | 253 |
|
|
2013
Q3 | $39K | Buy |
164
+43
| +36% | +$9.62K | 0.01% | 373 |
|
|
2013
Q2 | $26K | Buy |
+121
| New | +$25.9K | 0.01% | 431 |
|
Other funds holding BIIB
Trust Company of Vermont's BIIB Position: Q4 2025 in Review
Trust Company of Vermont reduced its Biogen (BIIB) stake by 63% in Q4 2025, selling an estimated $108K and leaving 389 shares worth $68.5K. The position accounts for ﹤0.01% of the portfolio, ranked #515.
Trust Company of Vermont first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.07M in Q3 2018. 998 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.
- Trust Company of Vermont held 389 shares of Biogen worth $68.5K as of Q4 2025.
- Trust Company of Vermont sold 660 Biogen shares in Q4 2025, an estimated $108K.
- Biogen made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #515 holding.
- Trust Company of Vermont first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
- Trust Company of Vermont's Biogen position peaked at $1.07M in Q3 2018.
- 998 funds tracked by Wall St. Rank held Biogen as of Q4 2025.
Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.